Evaluation of prognostic significance of hematological profiles after the intensive phase treatment in pulmonary tuberculosis patients from Romania.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
10
2020
accepted:
15
03
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
22
9
2021
Statut:
epublish
Résumé
We evaluated in this cohort study the predictive ability of 23 peripheral blood parameters and ratios for treatment outcomes after the 2-month intensive phase in patients with PTB. In 63 patients out of 90 that turned culture negative, a significant decrease in white blood cell count, neutrophils, monocyte, hemoglobin, platelet, plateletcrit, erythrocyte sedimentation rate, MLR, NLR, PLR and SII values after anti-TB therapy compared to pretreatment was observed (p <0.001). Logistic regression analysis generated a model of predictors consisting of nine covariates. Spearman's correlation analysis revealed significant positive correlations between NLR with NEU (r = 0.79, p<0.01), SII with NEU (r = 0.846, p<0.01), PLT with SII (r = 0.831, p<0.01), PLT with PCT (r = 0.71, p<0.01) and MPV with P-LCR (r = 0,897, p<0.01) in 63 patients out of 90 that turned culture negative after 2 months of treatment. ROC curve analysis indicated that all areas under the curve (AUC) revealed no statistically significant results, except lymphocyte for culture conversion. In summary, here we observed a set of hematological parameters that declined significantly as the disease was treated in patients that turned culture negative. Despite some limitations, our findings are useful for further studies aiming to identify hematological profiles that could predict the treatment outcome.
Identifiants
pubmed: 33793598
doi: 10.1371/journal.pone.0249301
pii: PONE-D-20-33128
pmc: PMC8016233
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249301Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Immunol. 2018 Nov 14;9:2637
pubmed: 30487797
Am J Clin Pathol. 1986 Feb;85(2):226-9
pubmed: 3946306
Am Surg. 1995 Mar;61(3):257-9
pubmed: 7887542
Can J Infect Dis Med Microbiol. 2019 May 27;2019:3270393
pubmed: 31263513
N Engl J Med. 2015 May 28;372(22):2127-35
pubmed: 26017823
BMC Hematol. 2016 Jan 08;16:1
pubmed: 26751690
Trends Microbiol. 2017 Aug;25(8):688-697
pubmed: 28366292
Int J Infect Dis. 2020 Jul;96:12-18
pubmed: 32289559
Lab Med. 2019 Jul 16;50(3):286-291
pubmed: 30753566
Pathog Dis. 2016 Apr;74(3):
pubmed: 26903072
J Intern Med. 2015 Apr;277(4):373-87
pubmed: 24717092
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
PLoS One. 2013 Aug 05;8(8):e71116
pubmed: 23940699
Int J Tuberc Lung Dis. 2002 Oct;6(10):909-12
pubmed: 12365578
Sci Rep. 2018 Feb 19;8(1):3290
pubmed: 29459661
J Microbiol Biotechnol. 2015 Apr;25(4):521-5
pubmed: 25341467
Multidiscip Respir Med. 2012 Oct 31;7(1):38
pubmed: 23114411
Lancet Infect Dis. 2013 Apr;13(4):362-72
pubmed: 23531389
Lancet Respir Med. 2014 Dec;2(12):943
pubmed: 25466339
Arch Med Sci. 2017 Mar 1;13(2):404-411
pubmed: 28261295
Sci Rep. 2019 Feb 4;9(1):1381
pubmed: 30718725
PLoS One. 2012;7(10):e46561
pubmed: 23049706
J Infect. 2019 May;78(5):339-348
pubmed: 30802469
Cytokine. 2019 Nov;123:154759
pubmed: 31226436
J Blood Med. 2020 Apr 01;11:115-121
pubmed: 32308514
Eur Respir J. 2016 Dec;48(6):1751-1763
pubmed: 27836953
Multidiscip Respir Med. 2014 Feb 28;9(1):11
pubmed: 24581084
Lancet Infect Dis. 2010 Feb;10(2):68-9
pubmed: 20113972
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
Sci Rep. 2018 Jul 12;8(1):10566
pubmed: 30002404
BMC Infect Dis. 2019 Nov 28;19(1):1006
pubmed: 31779590
Sci Rep. 2019 Mar 1;9(1):3284
pubmed: 30824727
PLoS One. 2015 Apr 29;10(4):e0125403
pubmed: 25923700
Antioxid Redox Signal. 2021 Feb 20;34(6):471-485
pubmed: 32559410
Nat Med. 2016 Oct;22(10):1094-1100
pubmed: 27595324
Front Immunol. 2020 May 27;11:962
pubmed: 32536917
Lancet. 2019 Apr 20;393(10181):1642-1656
pubmed: 30904262
Ann Intern Med. 1986 Apr;104(4):515-23
pubmed: 3954279
J Infect Dis. 2014 Feb 15;209(4):500-9
pubmed: 24041796
Exp Ther Med. 2016 Oct;12(4):2215-2219
pubmed: 27698714
Indian J Clin Biochem. 2016 Jul;31(3):332-5
pubmed: 27382206
Lancet Infect Dis. 2010 Jun;10(6):387-94
pubmed: 20510279
BMC Res Notes. 2018 Jun 28;11(1):414
pubmed: 29954436
BMC Infect Dis. 2016 Aug 05;16:368
pubmed: 27494953
Clin Chem Lab Med. 2007;45(8):1009-13
pubmed: 17867990
Ann Lab Med. 2013 Mar;33(2):105-10
pubmed: 23482854
J Int Med Res. 2019 Jul;47(7):2993-3007
pubmed: 31154881
BMC Infect Dis. 2019 Jul 29;19(1):667
pubmed: 31357936
Tuberculosis (Edinb). 2018 Jul;111:86-93
pubmed: 30029921
Lancet Respir Med. 2015 Mar;3(3):201-9
pubmed: 25726085
Front Immunol. 2018 Jul 30;9:1726
pubmed: 30105020
Oncotarget. 2018 Oct 19;9(82):35293-35299
pubmed: 30450158